Business Wire

IL-NEXTSENSE

3.12.2021 16:02:13 CET | Business Wire | Press release

Share
NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University

NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time.

NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rare.

The NextSense platform starts with longitudinal EEG data collected at the point of experience with biosensing earbuds that can be worn comfortably at night and as-needed throughout the day. The company envisions combining that data with environmental and behavioral patterns collected from smart devices and timely analysis from its team of neuroscientists to help doctors identify triggers, diagnose certain conditions and tailor treatment and medication recommendations in real-time.

At the AES Annual Meeting, NextSense detailed for the first time its key relationship with biopharma partner UCB. The company also revealed research and IP agreements with both Heraeus and UC San Diego, as well as a multi-dimensional collaboration with researchers at Emory University.

“We believe that technologies that enable earlier detection of seizures and improve the coordination of care for people living with epilepsy complement UCB’s strong heritage in epilepsy and portfolio of medicines,” said Colin Lake, Vice President of Digital Business Transformation for Neurology at UCB. “Being able to access meaningful data that NextSense can provide will allow us to capture insights and solve complex disease questions that will help epilepsy patients on their care journey achieve better outcomes.”

Each pharma and biotech company has partnered with NextSense to study how neurologists can better calibrate and manage treatment plans for epilepsy, sleep, and potentially other CNS disorders, using the company’s platform.

Emory University’s Brain Health Center, led by world-renowned physician-scientist Allan Levey, is the site of multiple NextSense studies and its first two clinical trials.

"We're excited for what this partnership means for both NextSense and Emory Brain Health," said Allan Levey, Founding Director of Goizueta Institute at Emory Brain Health. "Our work alongside Emory's Department of Biomedical Informatics signifies a notable step forward toward chronic ambulatory monitoring of brain physiology via EEG. With their earbuds allowing access for monitoring data over much longer periods of time, the initial findings and foundational work are very promising and showing how their efforts and technology has significant potential to revolutionize the approach to diagnosing and treating many neurological disorders in the future."

“We’ve assembled a dream team of collaborators,” said Jonathan Berent, Founder and CEO of NextSense. “It is a personal and professional thrill to partner with these innovators at the very top of their field. Our partners have worked with us shoulder-to-shoulder to methodically pursue what many people said was impossible. We are beyond excited to begin to show the world what we have achieved, starting with the scientific community at AES.”

NextSense is continuing to enroll participants in clinical trials focused on epilepsy and sleep. Eventually, the company hopes to leverage the long-term data collected to help establish biomarkers for brain health.

“Whether someone is living with epilepsy, struggling to stay alert, or seeking an elusive diagnosis for a neurological condition, we’re offering hope,“ said Jen Dwyer, Medical Director of NextSense. “We see our members from every angle, and we understand their unique pain points. We’re working towards a world where those who suffer from these conditions don’t have to choose between comfort and accuracy. And we’re just getting started.”

About NextSense, Inc.

NextSense is the foundation of a healthy brain.

We unlock brain health with real-world data insights and practical, scientific wisdom for daily living. Whether you are struggling to stay alert, living with something like epilepsy, seeking an elusive diagnosis for a neurological condition, we can help.

We are a passionate team of neuroscientists and venture operators on a mission to catalyze brain health in both science and culture.

To learn more, please visit: www.nextsense.io

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye